Safari Motahareh Solina, Obexer Dido, Baier-Bitterlich Gabriele, Zur Nedden Stephanie
CCB-Biocenter, Institute of Neurobiochemistry, Medical University of Innsbruck, Innsbruck, Austria.
Front Synaptic Neurosci. 2021 Feb 5;13:640495. doi: 10.3389/fnsyn.2021.640495. eCollection 2021.
Alterations in the processes that control α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) expression, assembly and trafficking are closely linked to psychiatric and neurodegenerative disorders. We have recently shown that the serine/threonine kinase Protein kinase N1 (PKN1) is a developmentally active regulator of cerebellar synaptic maturation by inhibiting AKT and the neurogenic transcription factor neurogenic differentiation factor-2 (NeuroD2). NeuroD2 is involved in glutamatergic synaptic maturation by regulating expression levels of various synaptic proteins. Here we aimed to study the effect of knockout on AKT phosphorylation and NeuroD2 levels in the hippocampus and the subsequent expression levels of the NeuroD2 targets and AMPAR subunits: glutamate receptor 1 (GluA1) and GluA2/3. We show that PKN1 is expressed throughout the hippocampus. Interestingly, not only postnatal but also adult hippocampal phospho-AKT and NeuroD2 levels were significantly elevated upon knockout. Postnatal and adult hippocampi showed enhanced expression of the AMPAR subunit GluA1, particularly in area CA1. Surprisingly, GluA2/3 levels were not different between both genotypes. In addition to higher protein levels, we also found an enhanced GluA1 content in the membrane fraction of postnatal and adult animals, while GluA2/3 levels remained unchanged. This points toward a very specific regulation of GluA1 expression and/or trafficking by the novel PKN1-AKT-NeuroD2 axis. Considering the important role of GluA1 in hippocampal development as well as the pathophysiology of several disorders, ranging from Alzheimer's, to depression and schizophrenia, our results validate PKN1 for future studies into neurological disorders related to altered AMPAR subunit expression in the hippocampus.
控制α-氨基-3-羟基-5-甲基-4-异恶唑丙酸受体(AMPAR)表达、组装和运输的过程发生改变与精神疾病和神经退行性疾病密切相关。我们最近发现,丝氨酸/苏氨酸激酶蛋白激酶N1(PKN1)通过抑制AKT和神经源性转录因子神经源性分化因子2(NeuroD2),是小脑突触成熟的发育活跃调节因子。NeuroD2通过调节各种突触蛋白的表达水平参与谷氨酸能突触成熟。在这里,我们旨在研究基因敲除对海马中AKT磷酸化和NeuroD2水平的影响,以及NeuroD2靶标和AMPAR亚基:谷氨酸受体1(GluA1)和GluA2/3随后的表达水平。我们发现PKN1在整个海马中均有表达。有趣的是,基因敲除后不仅出生后而且成年海马中的磷酸化AKT和NeuroD2水平均显著升高。出生后和成年基因敲除海马中AMPAR亚基GluA1的表达增强,特别是在CA1区。令人惊讶的是,两种基因型之间的GluA2/3水平没有差异。除了更高的蛋白水平外,我们还发现出生后和成年基因敲除动物的膜组分中GluA1含量增加,而GluA2/3水平保持不变。这表明新的PKN1-AKT-NeuroD2轴对GluA1表达和/或运输有非常特异性的调节。考虑到GluA1在海马发育以及从阿尔茨海默病到抑郁症和精神分裂症等多种疾病的病理生理学中的重要作用,我们的结果验证了PKN1在未来研究与海马中AMPAR亚基表达改变相关的神经系统疾病中的作用。